Benzodiazepine derivatives for treating hepatitis C infection

Details Benzodiazepine derivatives for treating hepatitis C infection Benzodiazepine derivatives for treating hepatitis C infection

2005-09-19

2011-10-18

Wang, Shengjun (Department: 1627)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C514S221000

Reexamination Certificate

active

08039616

ABSTRACT:
Use of a benzodiazepine of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing a hepatitis C infection, wherein: —R1represents C1-6alkyl, aryl or heteroaryl; —R2represents hydrogen or C1-6alkyl; —each R3is the same or different and represents halogen, hydroxy, C1-6alkyl, C1-6alkoxy, C1-6alkylthio, C1-6haloalkyl, C1-6haloalkoxy, amino, mono(C1-6alkyl)amino, di(C1-6alkyl)amino, nitro, cyano, —CO2R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O)2R′, —NH—S(O)2R′, —S(O)NR′R″ or —S(O)2NR′R″, wherein each R′ and R″ is the same or different and represents hydrogen or C1-6alkyl; —n is from 0 to 3; —R4represents hydrogen or C1-6alkyl; —R5represents C1-6alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6alkyl)-, heteroaryl-(C1-6alkyl)-, carbocyclyl-(C1-6alkyl)-, heterocyclyl-(C1-6alkyl)-, aryl-(C1-6hydroxyalkyl)-, heteroaryl-(C1-6hydroxyalkyl)-, carbocyclyl-(C1-6hydroxyalkyl)-, heterocyclyl-(C1-6hydroxyalkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or —XR6; —X represents —CO—, —S(O)— or —S(O)2—; and —R6represents C1-6alkyl, hydroxy, C1-6alkoxy, C1-6alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6alkyl)-, heteroaryl-(C1-6alkyl)-, carbocyclyl-(C1-6alkyl)-, heterocyclyl-(C1-6alkyl)-, aryl-(C1-6alkyl)-O—, heteroaryl-(C1-6alkyl)-O—, carbocyclyl-(C1-6alkyl)-O—, heterocyclyl-(C1-6alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C1-6alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6alkyl)-, heteroaryl-(C1-6alkyl)-, carbocyclyl-(C1-6alkyl)- or heterocyclyl-(C1-6alkyl)-.

REFERENCES:
patent: 3344136 (1967-09-01), Bell et al.
patent: 4628084 (1986-12-01), Bock et al.
patent: 4820834 (1989-04-01), Evans et al.
patent: 5633251 (1997-05-01), Claremon et al.
patent: 5852010 (1998-12-01), Graham et al.
patent: 2002/0142940 (2002-10-01), Graham et al.
patent: 0 491 218 (1992-06-01), None
patent: 0167919 (1993-05-01), None
patent: 0284256 (1994-06-01), None
patent: 93/17011 (1993-09-01), None
patent: 95/14471 (1995-06-01), None
patent: 95014694 (1995-06-01), None
patent: 97/36879 (1997-10-01), None
patent: 98/24805 (1998-06-01), None
patent: 0004900 (2000-02-01), None
patent: 00/12547 (2000-03-01), None
patent: 00/66106 (2000-11-01), None
patent: 01/00611 (2001-01-01), None
patent: 01/74783 (2001-10-01), None
patent: 01/90084 (2001-11-01), None
patent: 01/92235 (2001-12-01), None
patent: 03/015703 (2003-02-01), None
patent: 03061632 (2003-07-01), None
patent: 2004/026843 (2004-04-01), None
patent: 2005/089770 (2005-09-01), None
patent: 2005090319 (2005-09-01), None
Bock et al; Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists, Journal of Medicinal Chemistry, 1993, pp. 4276-4292, vol. 36 (26).
Butcher et al; Preparation of 3-amino-1,4-benzodiazepin-2-ones via direct azidation with trisyl azide, Tetrahedron Letters, 1996, pp. 6685-6688, vol. 37, No. 37.
Evans et al; Methods for Drug Discovery: Development of potent, selective, orally effective cholecystokinin antagonists, Journal of Medicinal Chemistry, 1988 pp. 2235-2246 vol. 31, No. 12.
Haradahira et al; Synthesis and Evaluation of 11C-Labeled Nonpeptide Antagonists for Cholecystokinin Receptors: [11C]L-365,260 and [11C]L-365,346, Nuclear Medicine and Biology, 1998, 25(3), 203-208.
Rawson et al; Stereochemistry of the Benzodiazepine Based RAS Farnesyltransferase Inhibitors, Bioorganic and Medicinal Chemistry Letters, 1995, 5 (13):1335-1338.
Reider et al; Crystallization-induced asymmetric transformation: stereospecific synthesis of a potent peripheral CCK antagonist, Journal of Organic Chemistry, 1987 pp. 955-957 vol. 52.
Shi et al; Crystallization-induced asymmetric transformation: stereospecific synthesis of L-768,673, Tetrahedron, 1999 pp. 909-918 vol. 55, No. 4.
Search report citing: Giudice, et al; Synthesis of 2- and 3- amino-1,4-benzodiazepines, Farmaco, Edizione Scientifica (1982), 37(5), 343-52.

Affiliated with

Also associated with

Rating

Benzodiazepine derivatives for treating hepatitis C infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzodiazepine derivatives for treating hepatitis C infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodiazepine derivatives for treating hepatitis C infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4302694